Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed …
The stock ended at $165.65, rising 3.32% from the last trading session. The Company's shares have gained 3.59% in …
KHNL28d
In a report published Friday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating on Catalyst …
We issued an updated research report on Catalyst Pharmaceuticals, Inc. CPRX on Mar 22. Catalyst’s share price has increased significantly by 60% year to date, compared with the Zacks classified Medical Drugs industry's gain of 2.1%. …
The stock ended at $165.65, rising 3.32% from the last trading session. The Company's shares have gained 3.59% in …
Over the last six months, Celgene was up 18.2% while Gilead was down 13.2% (See the last biotech stock roundup here: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal). While the above ideas are being shared with the …